Diagnosis and Management of Viral Respiratory Tract Infections in High Risk Allogeneic or Autologous Blood and Marrow Transplant Recipients or Leukaemia patients *

Scope
This document provides guidance on the diagnosis and management of viral respiratory tract infections (RTI) in high risk patient groups*.

*High risk patient groups (HRPG) include:
• Receipt of allogeneic or autologous BMT within past 100 days and those >100 days with continued immunosuppression
• Receipt of allogeneic or autologous BMT and absolute lymphocyte count of less than 0.3 x 10⁹/L
• Receipt of allogeneic BMT with active GvHD on immunosuppression including corticosteroids
• Leukaemia patients with an absolute neutrophil count less than 0.5 x 10⁹/L

Introduction
Viral RTI are common in the high risk patient groups (HRPG) and include:
• Respiratory Syncytial Virus (RSV)
• Parainfluenza viruses
• Influenza A & B
• Adenovirus/Metapneumovirus/Rhinovirus/Coronaviruses

Although these viruses tend to show a seasonal variation in the general population this is not necessarily the case for immunocompromised individuals. Patients within the HRPG who develop viral upper respiratory tract infection should be considered for antiviral therapy to reduce the risk of pneumonia and death.

Diagnosis
All HRPG (<100 days and those >100 days with continued immunosuppression/cGVHD or with other high risk features increasing risk of progression from URTI to LRTI e.g. receiving chemotherapy, neutropenia, lymphopenia etc.) should have a throat swab taken ideally at the onset of symptoms.

Samples:
• A ‘flocked’ swab in virus transport medium should be used; the swab needs to be swept deeply in the throat, almost causing the patient to gag. Swab and medium are available on the Haematology Ward and in the Out Patient Department.

Investigations:
• Swabs should be sent to the Microbiology Department at the John Radcliffe Hospital and the clinical details should clearly indicate that this is a BMT/Leukaemia patient.

On a correct EPR encounter, request Respiratory virus screen PCR (performed daily). The respiratory panel (Biofire) includes adenovirus, coronaviruses 229E, HKU1, NL63, OC43, and MERS-CoV, human metapneumovirus, human rhinovirus/enterovirus, influenza A, influenza A H1, influenza A H1-2009, influenza A H3, influenza B, parainfluenza viruses 1-4, respiratory syncytial virus, Bordetella pertussis and parapertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae.

• Results of the Respiratory panel should be available on same day, please contact lab if results not in EPR.
Minimising spread

- Inpatients with suspected or confirmed viral RTI should be nursed on the Haematology Ward in a negative or neutral pressure side room with the door closed.
- Strict isolation is required in both cases. The patient should be confined to their room to avoid social contact with other immunocompromised patients. These infections are spread by close contact with infected secretions, by large particle aerosols and by fomites.
- Standard barrier nursing precautions plus vigilant hand washing or alcohol hand rub is essential.
- Health care workers should be aware of their ability to be a vector in this setting, and wear and dispose of PPE appropriately.
- Health care workers should be immunised with the seasonal influenza vaccine.
- Ensure patients practice good respiratory hygiene by covering the mouth if coughing or sneezing, and by safe disposal of oral and nasal secretions
- All equipment removed from the room (e.g. infusion pumps) should be cleaned with a detergent and water solution, ensuring that this is not against the manufacturer’s guidelines. It is imperative that the equipment is then dried thoroughly.
- All surfaces in the room should be thoroughly cleaned daily.
- Full terminal clean of the room following patient discharge.
- Multiple, confirmed cases should be cohort nursed, in a 2-bedded bay with the door closed.
- Follow guidelines as per protective isolation protocol (B.6.0)

Visitors should be advised to be vigilant about hand washing or alcohol hand rub and avoid contact with all other patients on the ward. They should not use the day room or other ward facilities. Relatives must not visit the ward if they have respiratory symptoms.

Outpatients

In cases of proven infection, provision should be made for the patient to be directed straight to a consultation room to avoid prolonged contact with other immunocompromised patients in waiting/treatment areas. Staff should apply the above precautions.

Management

1. **Respiratory Syncytial Virus (RSV)**

   Respiratory Syncytial Virus (RSV) is a paramyxovirus. It causes upper and lower respiratory tract infections. It predominantly affects children, elderly, and those with severe immunodeficiency. The treatment regimen is not standardized amongst institutions due to a lack of literature which clearly delineates the optimal treatment regimen. Therefore, various formulations and dosing regimens of ribavirin, either alone or in combination with an immunomodulator, have been used for the treatment of RSV infections.

   **Investigations:** RSV PCR, CXR, Serum Ig’s and electrophoresis and consider CT chest if chest CXR and clinical examination not confirmatory of LRTI.

   **Treatment:**

   Empiric use of ribavirin is not recommended; only patients who have a positive molecular test for RSV and meet one of the two criteria below should be considered for ribavirin therapy:

   - Symptoms and signs of lower respiratory tract infection (clinical, imaging).
- Treatment may be considered occasionally in patients with upper respiratory tract infection. The following are associated with high risk for progression from URTI to LRTI: pre-engraftment, lymphopenia <0.3 x 10^9/l, > 60 years, GVHD, mismatched, haploidentical related or umbilical cord blood donor transplant, neutropenia <0.5 x 10^9/l.

It is generally only patients on immunosuppression or within 12 months of transplant who will require therapy.

**Immunoglobulin:**
- Consider commencement of IV Immunoglobulin (in combination with ribavirin) at a total treatment dose of 2g/kg administered over 2-4 days. All cases should be discussed with Dr Siraj Misbah (Consultant Immunologist) or if Dr Misbah is unavailable, Dr John Reynolds (contactable via email).
Ribavirin

Ribavirin is unlicensed for the treatment of RSV. Various dosing schedules and regimes have been used in different publications from retrospective and prospective studies. The dosing regimen of ribavirin is therefore not standardized amongst institutions/guidelines due to a lack of literature which clearly delineates the optimal treatment regimen.

- Oral Ribavirin (available in tablet or liquid formulation) should be used whenever possible.
- IV Ribavirin should be used where oral route is not appropriate (e.g. malabsorption) or unavailable.

**Dosing in normal renal function (CrCl > 50ml/min):**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dosing Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral dose</td>
<td>15-20 mg/kg/day divided into TDS administration for 7-10 days</td>
</tr>
<tr>
<td></td>
<td>Dose should be rounded to the nearest 200 mg</td>
</tr>
<tr>
<td></td>
<td>To be taken with food</td>
</tr>
<tr>
<td>Intravenous</td>
<td>Day 1: 600 mg loading dose, then 200 mg TDS</td>
</tr>
<tr>
<td></td>
<td>Day 2: 400 mg TDS</td>
</tr>
<tr>
<td></td>
<td>Day 3: Increase the dose to a maximum of 10 mg/kg TDS</td>
</tr>
</tbody>
</table>

**Dosing in impaired renal function (CrCl < 50ml/min):**

Ribavirin accumulates in patients with decreased renal function; substantial increases in ribavirin plasma concentrations are seen in patients with creatinine clearance < 50 ml/min. Considerations should be made on the risk/benefit to the specific patients with close monitoring of side effects particularly haemolytic anaemia. The European Guideline (EUCIL4, 2013) for ribavirin dose adjustments in renal dysfunction make the following recommendation:

**Renal Dose adjustments** (for both oral and intravenous routes):

<table>
<thead>
<tr>
<th>CrCl</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-50 ml/min</td>
<td>200 mg TDS</td>
</tr>
<tr>
<td>10-30 ml/min</td>
<td>200 mg once daily</td>
</tr>
</tbody>
</table>

**Ribavirin monitoring**

FBC (baseline then twice weekly while on therapy) if Hb is falling add a reticulocyte count, U&E, serum creatinine, LFTs, sign/symptoms of adverse effects. Pregnancy test in appropriate groups prior to commencement (see below)

**Haemolytic anaemia:** Ribavirin does accumulate in patients with decreased renal function and patients should be carefully monitored for toxicity such as haemolytic anaemia.

**Patients should have a FBC, Reticulocyte count, LDH, Bilirubin twice weekly one week after commencing Ribavirin and then weekly for a period of 3 weeks. Should Hb begin to drop, consideration should be given to arrange a blood transfusion. This can be arranged at patient’s local hospital.**

**FBC monitoring and blood transfusions can be arranged by the BMT specialist nurses.** In a recent series of Oxford patients (November 2015/December 2017) 4/24 BMT patients (16.7%) were admitted with haemolytic anaemia following Ribavirin.

**Warnings/precautions:**

A warning exists for haemolytic anaemia which may occur. Patients with significant or unstable cardiac disease should avoid use of ribavirin due to the potential for the haemolytic anaemia leading to a myocardial infarction. Elderly patients may be more prone to adverse events such as anaemia.
Experience with the use of ribavirin for treatment of hepatitis C indicates that anaemia usually occurs within 1-2 weeks after initiation of oral ribavirin therapy.

For those patients that have renal impairment, dose adjustments or discontinuation of therapy may be needed.

**Pregnancy:** A warning also exists regarding the teratogenic effects of ribavirin observed in animal studies. Exclude pregnancy before treatment; effective contraception essential during treatment and for 4 months after treatment in women and for 7 months after treatment in men and the female partners of male patients treated with ribavirin.

**Hazardous agent:** This is a hazardous agent and special handling and disposal is required. The drug should be handled as per cytotoxic handling requirements. The tablets should not be broken or crushed.

2. **Influenza A & B**
   Testing as per above
   On positive result commence Oseltamivir as per Public Health England guidelines. Oseltamivir is also be indicated for patients with complicated Influenza A or B infection after 48 hours of symptoms (consider discussion with Churchill ID Consult team bleep 5039). Five days is the minimum duration for treatment, and in the immunocompromised population may be continued for longer, depending on response.

   Zanamivir (Diskhaler) should be used first line when the dominant circulating strain has a high risk of oseltamivir resistance.

   The current Public Health England recommendations on post-exposure prophylaxis for influenza infection should be followed.

3. **Parainfluenza (HPIV)**
   Treatment of HPIV is generally supportive together with respiratory isolation. Reduction of steroid dosage where feasible and appropriate may be a valid approach. No proven anti-viral agent exists although some agents are in early phase clinical trials. Ribavirin may be considered in selected high-risk patients with LRTI, based on anecdotal reports. Discuss with Consultant Microbiologist/Churchill Infection consult team (bleep 5039). Consider IVIG therapy in this patient group.

4. **Adenovirus**
   Adenovirus infection post BMT may be asymptomatic or present as an URTI, enteritis or cystitis. Adenovirus is now recognised as a significant pathogen in children following BMT with reported mortality rates as high as 60% in disseminated infection. Adenovirus can be detected in blood, stool, urine, throat swab or NPA/NPW. Confirmed cases should be discussed with Consultant Microbiologist/Churchill Infection consult team (bleep 5039). Antiviral therapy may be advised. Cidofovir is currently very difficult to obtain, and ribavirin may be considered in selected high-risk patients with LRTI, based on anecdotal reports.
References:


Hirsch et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus. CID 2013:56; 258-266


Authors
Tim Littlewood, BMT Programme Director, Version 1, 2004
Claire Humphries, Cancer Pharmacist, Version 1, 2004

This is a controlled document and therefore must not be changed
# Audit
These processes are subject to the OxBMT audit programme

# Circulation
NSSG Haematology Website

## Review

<table>
<thead>
<tr>
<th>Name</th>
<th>Revision</th>
<th>Date</th>
<th>Version</th>
<th>Review date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Katie Jeffrey, Consultant Virologist Denise Wareham, BMT Coordinator</td>
<td>Compliance with Jacie standards, review of process, insertion of Jacie standards into document Compliance with Trust guidelines</td>
<td>Jan 2013</td>
<td>3.0</td>
<td>Jan 2015</td>
</tr>
<tr>
<td>Sandy Hayes, Quality Manager. Dr Robert Danby, Consultant Haematologist</td>
<td>Reduction in duration of oral ribavirin administration to 7 days. Changes to patient follow up guidance</td>
<td>Jan 2016</td>
<td>4.1</td>
<td>Dec 2017</td>
</tr>
<tr>
<td>Sandy Hayes, Quality Manager</td>
<td>Removal of line regarding assay sensitivity</td>
<td>Mar 2016</td>
<td>4.2</td>
<td>Dec 2017</td>
</tr>
<tr>
<td>Cheukie-Kie Cheung, Specialist Cancer Pharmacist Dr Katie Jeffery, Consultant Virologist</td>
<td>Minor amendment</td>
<td>Feb 2017</td>
<td>4.3</td>
<td>2017 when lab changes in place</td>
</tr>
<tr>
<td></td>
<td>Minor amendments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lara Rowley BMT NP Dr Katalin Balassa, BMT Fellow Dr Katie Jeffery, Consultant Virologist</td>
<td>Additions and amendments: HRPG, BCSH guidelines Ribavirin dosing, IVIG Generic changes</td>
<td>Apr 2018</td>
<td>4.4</td>
<td>Apr 2020</td>
</tr>
</tbody>
</table>